Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
The latest announcement is out from IXICO plc ( (GB:IXI) ).
IXICO plc announced a commercial agreement with PETNET Solutions Inc, part of Siemens Healthineers, to supply diagnostic imaging agents for its neuroimaging services. This partnership is part of IXICO’s strategy to enhance its offerings in clinical trials, particularly for Alzheimer’s disease research, by integrating PET tracers that assess β-amyloid plaque and tau neurofibrillary tangles, thereby further strengthening its market position in neurodegenerative research.
More about IXICO plc
IXICO plc is a global leader in neuroscience imaging, focusing on the advancement of therapy research for neurological disorders using its AI-driven platform. The company is dedicated to transforming investigational therapies for diseases such as Huntington’s, Parkinson’s, and Alzheimer’s by providing valuable insights through advanced medical image analysis.
YTD Price Performance: -8.00%
Average Trading Volume: 74,029
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £10.66M
Find detailed analytics on IXI stock on TipRanks’ Stock Analysis page.
